Guided Therapeutics (GTHP) Operating Expenses (2010 - 2025)

Guided Therapeutics has disclosed Operating Expenses across 16 years of filings, most recently posting $1.2 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $1.2 million, up 119.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 million (up 39.46% YoY), and the FY2025 annual result was $2.9 million, up 39.48% from the prior year.
• Operating Expenses came in at $1.2 million for Q4 2025 at Guided Therapeutics, up from $520000.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.5 million in Q2 2023 to a low of $363000.0 in Q1 2024.
• The 5-year median for Operating Expenses is $591000.0 (2021), against an average of $706850.0.
• Across the five-year window, Operating Expenses surged 240.08% in 2021 and plunged 57.59% in 2024, its largest moves.
• Guided Therapeutics' Operating Expenses stood at $476000.0 in 2021, then surged by 82.56% to $869000.0 in 2022, then sank by 42.35% to $501000.0 in 2023, then climbed by 6.19% to $532000.0 in 2024, then jumped by 119.55% to $1.2 million in 2025.
• The last three Operating Expenses figures came in at $1.2 million (Q4 2025), $520000.0 (Q3 2025), and $842000.0 (Q2 2025), per Business Quant data.